Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05665348
Title Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)
Acronym TRIPLET
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Federation Francophone de Cancerologie Digestive
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
Chu Henri Mondor RECRUITING Créteil France Details
Chu Francois Mitterand RECRUITING Dijon France Details
Chu Dupuytren RECRUITING Limoges France Details
Chu La Croix Rousse RECRUITING Lyon France Details
Chu L'Archet RECRUITING Nice France Details
Chu La Pitie Salpetriere RECRUITING Paris France Details
Chu Saint Antoine RECRUITING Paris France Details
Chu Haut Leveque RECRUITING Pessac France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field